Abstract. The aim of the present study was to investigate the effect of Forkhead family transcription factor P3 (Foxp3) knockdown on the function of cluster of differentiation (CD)4 + CD25 + regulatory T cell (Tregs) and the tumor growth of a hepatocellular carcinoma (HCC) mouse model. 
Introduction
Hepatocellular carcinoma (HCC) is one of the most challenging malignant tumors, with a high morbidity and mortality in China (1, 2) . Although progress has been made in surgery (transplant, embolization or resection); radiation therapy, chemotherapy and ablation, tumor recurrence and metastasis remain difficult to treat (3) . Therefore, investigations into the molecular mechanism of recurrence and metastasis of HCC, and less invasive but more effective therapeutic methods for clinical HCC treatment are required.
Immunotherapy has been applied in the treatment of HCC in early clinical trials due to its characteristics: Systemic, nontoxic and long-lived anti-tumor activity (4) . Previous studies have demonstrated that the tumor microenvironment may be established by the regulation of lymphocytes, and then serves a vital role in the progression of tumors through immunity and inflammation (5, 6) . It is well known that cluster of differentiation (CD)4 + CD25 + regulatory T cells (Tregs) contribute to the growth of malignant tumors through suppressing immune surveillance (7) . Forkhead family transcription factor P3 (Foxp3) is specifically expressed in Tregs and serves an important role in the negative immunoregulatory function of Tregs in mice and humans (8, 9) . A previous study has indicated that in murine tumor models, downregulated Foxp3 inhibits the tumor growth of CD4 + CD25 + Tregs, as observed in leukemia (10 Currently, the application of ultrasound-targeted microbubble destruction (UTMD) for gene delivery has become a focus of research due to its low immunogenic, non-invasive, targeted and high-efficiency characteristics (13, 14) . UTMD has been demonstrated to efficiently deliver genes to cells, myocardium and solid tumors (15) (16) (17) . In the present study, the expression of Foxp3 was downregulated through UTMD-mediated delivery of Foxp3-microRNA (miRNA) and Foxp3-short hairpin RNA (shRNA) in CD4 + CD25 + Tregs to a HCC mice model, respectively. Whether Foxp3 knockdown was able to inhibit the negatively immunoregulatory function of CD4 + CD25 + Tregs and suppress the tumor growth of HCC through improving the immune microenvironment was then assessed.
Materials and methods
Patients. The current study recruited a total of 50 patients (28- Preparation of microbubble. SonoVue powder (Bracco, Milan, Italy) was dissolved in 5 ml normal saline. Following 5 min oscillation, microbubbles were evenly distributed.
Microbubbles with a density of 2x10 8 -5x10 8 /ml, diameter of 2.5-6.0 µm and concentration of 5 mg/ml were observed under a light microscope (Olympus Corporation, Tokyo, Japan).
Cell transfection and grouping.
Tregs with a concentration of 1x10 6 /ml were resuspended in serum-free RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.), and 1.5-2x10 5 cells were seeded into each well of a 96-well plate (Corning Incorporated, Corning, NY, USA). Then, the cells were divided into 7 groups as follows: i) Control group, 90 µl medium + 10 µl control plasmid; ii) SonoVue microbubbles + Foxp3-miRNA plasmid (MB + P) group, 80 µl medium + 20 µl mixture of microbubbles and Foxp3-miRNA plasmid (1:1); iii) ultrasound + Foxp3-miRNA plasmid (US + P) group, 90 µl medium + 10 µl Foxp3-miRNA plasmid with ultrasonic irradiation; iv) ultrasound + SonoVue microbubbles + Foxp3-miRNA plasmid (US + MB + P) group, 80 µl medium + 20 µl mixture of microbubbles and Foxp3-miRNA plasmid (1:1) with ultrasonic irradiation; v) Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) + Foxp3-miRNA plasmid (L + P) group, 90 µl medium + 10 µl Foxp3-miRNA plasmid + 1 µl Lipofectamine ® 2000; vi) Ul trasound + Lipofectamine2000 + Foxp3-miRNA plasmid (US + L + P) group, 90 µl medium + 10 µl Foxp3-miRNA plasmid + 1 µl Lipofectamine2000 with ultrasonic irradiation; vii) Ultrasound + SonoVue microbubbles + Lipofectamine 2000 + Foxp3-miRNA plasmid (US + MB + L + P) group, 80 µl medium + 20 µl mixture of microbubbles and Foxp3-miRNA plasmid (1:1) + 1 µl Lipofectamine ® 2000 with ultrasonic irradiation. The groups with ultrasonic irradiation were exposed to irradiation conditions with (MI=1.4; exposure time=150 sec) using IU22 ultrasonic equipment (Philips Healthcare, DA Best, The Netherlands). Following transfection for 24 h, the transfection efficiency was observed under fluorescence microscope (Olympus Corporation) and detected by FACSCalibur flow cytometer (BD Biosciences) as previously described (19) . Results were analyzed using FACSComp (version5.1) software (BD Biosciences).
Detection of Tregs activity. Following 24 h transfection, 10 µl
Cell Counting Kit (CCK)8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added into each well and cultured at 37˚C for 4 h. Then, the absorbance was read at 460 nm using a microplate reader (Molecular Devices LLC, Sunnyvale, CA, USA). The cell survival rate was calculated as optical density (OD) test group-blank group /OD control group-blank group .
Inhibition effect of Tregs on CD4
+ CD25 -T cells. Two healthy volunteers (one 40-year-old male weighing 75 kg and one 45-year-old female weighing 63 kg) were recruited at The First Affiliated Hospital of Harbin Medical University in May 2014. Written informed consent was received from healthy volunteers and fasting peripheral blood samples were collected. PBMCs were separated from the peripheral blood. Tregs in the control group (90 µl medium + 10 µl control plasmid) and optimal transfection group (US + MB + L + P) were collected and co-cultured with CD4 + CD25 -T cells and PBMCs. CD4 + CD25 -T cell activity was detected using the CCK8 assay according to the manufacturer's protocol. The proliferation-inhibition ratio of CD4 + CD25 -T cells was calculated as OD cells without
Tregs-cells with Tregs /OD cells without Tregs . Supernatant was collected to detect the contents of interferon-γ (IFN-γ) and interleukin-2 (IL-2) secreted by CD4 + CD25 -T cells in addition to IL-10 and transforming growth factor-β (TGF-β) secreted by Tregs using the corresponding ELISA kits (IFN-γ, E0110345; IL-2, E0110308; IL-10, E0110023; TGF-β, E01T0058; Shanghai BlueGene Biotech Co., Ltd., Shanghai, China) according to the manufacturer's protocol.
Animal model and grouping. Ethical approval was obtained from the Ethics Committee of the Animal Laboratory Center of the First Affiliated Hospital of Harbin Medical University. A total of 21 healthy male C57BL/6 mice (8 weeks old; 18-22 g) were purchased from the Animal Laboratory Center of the first affiliated hospital of Harbin medical university, and acclimatized to a 12 h light/dark cycle at 21˚C with 60-70% relative humidity and given free access to food and water for a week prior to the trial. For the HCC mice model, 200 µl Hepa1-6 cells (5x10 7 /ml; Shanghai Cell Bank of Chinese Academy of Sciences, Shanghai, China) were transplanted subcutaneously into the right flanks of mice in the model group (n=18). The other 3 mice were treated with normal saline as a control. Following 7 days, the 18 mice in the model group were randomly and equally assigned to 2 groups (n=9): HCC and treatment groups. Mice in the treatment group were treated with microbubbles and Foxp3-shRNA plasmid, 200 µl intravenously and 300 µl directly into tumors. Mice in HCC group were injected with an equal dose of normal saline in the same method. Following injection, tumors were immediately irradiated by ultrasound for 300 sec. The treatment was repeated every 3 days, for 21 days, a total of 7 times.
Detection index. Prior to each treatment, the long diameters (a) and short diameters (b) of the tumor were detected and tumor volume was calculated as follows: 1/6πa 2 b. Tumor growth curves were constructed according to the tumor volume. Following 1 week of treatment, all mice were sacrificed using 1.5% pentobarbital (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) with a dose of 375 mg/kg and the tumors were weighed. The tumor inhibition rate=(mean tumor weight in control group-mean tumor weight in experimental group)/mean tumor weight in control group. In addition, following treatment for 1 week, blood samples were collected. The content of CD4 + and CD25 + T cells were detected by staining with CD4-FITC and CD25-Allophycocyanin conjugated antibodies (1:50; cat. nos. 553047 and 557192; BD Biosciences), respectively, using FACSCria (BD Biosciences). Briefly, the cells (1x10 7 cells/ml, 0.1 ml) were stained with CD4-FITC or CD25-Allophycocyanin conjugated antibodies for 30-40 min at room temperature in the dark. Cells were washed with PBS and samples were fixed in 1% Statistical analysis. Statistical analysis was performed by SPSS 12.0 statistical analysis software (SPSS, Inc., Chicago, IL, USA). Data were expressed as the mean ± standard deviation and analyzed by one-way analysis of variance followed by a least significance differences test. P<0.05 was considered to indicate statistically significant differences.
Results

Comparison of transfection efficiency between groups.
Following 24 h of transfection, fluorescence measurements indicated that no green fluorescent cells were present in the control group, whereas different numbers of green fluorescent cells were observed in the other six groups. US + MB + L + P group had more green fluorescent cells than the other five groups (Fig. 1A) . In addition, flow cytometry analysis demonstrated that transfection efficiency was 0, 2.17±0.57, 3.34±0.43, 10.39±1.65, 24.58±2.48, 27.61±3.40 and 46.59±4.10% in the MB + P, US + P, US + MB + P, L + P, US + L + P, and US + MB + L + P groups, respectively (Fig. 1B) , which were consistent with fluorescence measurements. In addition, western blot analysis demonstrated that the expression of Foxp3 was inhibited following transfection with the Foxp3-miRNA plasmid (Fig. 1B) . Compared with the control group, following transfection with Foxp3-miRNA plasmid for 24 h, the survival rate of Tregs was significantly inhibited in the other groups (P<0.01, Fig. 2A) . In addition, the present study demonstrated that the mean tumor volume and tumor weight were markedly lower in the treatment group compared with the HCC group (1.251±0.244 vs. 2.742±0.221 cm 3 and 1.328±0.163 vs. 3.086±0.227 g; P<0.01; data not shown). Tumor growth curves also indicated that the average tumor volume was markedly inhibited by UTMD-mediated Foxp3-shRNA ( Fig. 2B and C) . (Fig. 3) indicated that compared with the control group, the ratio of Tregs/CD4 + T cells was increased in the HCC group (4.89±0.81 vs. 3.11±0.65%; P<0.05; data not shown); however, once treated with Foxp3-shRNA, the ratio of Tregs/CD4 + T cells decreased, to below the HCC group (3.28±0.75 vs. 4.89±0.81%; P<0.05; data not shown).
Effect of UTMD-mediated Foxp3-shRNA on Tregs and CD4 + T cells in HCC model of mice. Flow cytometry analysis
Effect of UTMD-mediated Foxp3-shRNA on the levels of IL-10, TGF-β, IFN-γ, IL-2 and VEGF in serum of HCC
mouse model. ELISA analysis demonstrated that the level of IL-10, TGF-β and VEGF increased, whereas the levels of IFN-γ and IL-2 decreased in HCC group, compared with the control group (P<0.05; Table V) . However, compared with the HCC group, the level of IL-10, TGF-β and VEGF decreased, while the level of IFN-γ and IL-2 increased in the treatment group (P<0.05; Table V) .
Discussion
UTMD-mediated gene therapy has been applied both in vitro and in vivo (17) . In contrast with UTMD, Lipofectamine ® 2000
is a common non-viral vector characterized by a low immunogenicity and high safety but low efficiency, non-targeting and increased cytotoxicity (20, 21) . The present study demonstrated that UTMD or Lipofectamine ® 2000 may effectively transfect Foxp3-miRNA into Tregs, with maximum transfection efficiency observed in the US + MA + L + P group. These results suggested that the combination of UTMD with Lipofectamine ® 2000 may enhance transfection efficiency.
Tregs was a major factor in the suppression of the tumor-specific immune response in patients with HCC, and the elimination or suppression of Tregs function may effectively enhance the antitumor immune response (22) . Foxp3 has been demonstrated to regulate the immunosuppressive function of Tregs (23) . Previous studies have indicated that the immune -T cells. Furthermore, Foxp3 is able to suppress the production of IFN-γ and IL-2 secreted by effector T cells, while upregulating the level of IL-10 and TGF-β secreted by Tregs (27) . Furthermore, Foxp3 + Tregs is able to suppress the activation of T cells and inhibit the proliferation of effector CD4 + T cells (28) . Notably, Foxp3 knockdown may enhance tumor immunity (29) . Consistently, the current study demonstrated that Foxp3 It has been suggested that the immunosuppressive function of Tregs, at least partially, contributed to the proliferation of tumor cells (30) . A previous study indicated that a depletion of Tregs may enhance tumor immunity and inhibit tumor growth in patients with HCC (12) . Notably, the present study revealed that UTMD-mediated Foxp3-shRNA inhibited the tumor growth in HCC model mice, suggesting that UTMD-mediated Foxp3-shRNA may inhibit the function of Tregs. In addition, the current study also indicates that the downregulation of Foxp3 reduced the ratio of Tregs/CD4 + T cells. Following treatment with Foxp3-shRNA, the level of IL-10 and TGF-β decreased, while the level of IFN-γ and IL-2 increased, in the current study. These results indicate that the downregulation of Foxp3 enhanced the immunologic function and anti-tumor effect. Furthermore, the present study also demonstrated that UTMD-mediated Foxp3-shRNA reduced the level of VEGF. It has been demonstrated that VEGF promotes the Tregs group. Data are presented as mean ± standard deviation. Treg, regulatory T cell; Foxp3, forkhead family transcription factor P3; miRNA, microRNA; IFN-γ, interferon-γ; IL-2, interleukin-2; TGF-β, transforming growth factor-β; CD, cluster of differentiation; PBMC, peripheral blood mononuclear cell. formation of tumor angiogenesis and inhibits the apoptosis of tumor cells (31) . These results indicate that UTMD-mediated Foxp3-shRNA may partially inhibit the tumor growth in HCC mice through suppressing the production of VEGF.
In conclusion, the current study demonstrated that the combination of UTMD with Lipofectamine ® 2000 may be the optimal choice to enhance the transfection efficiency in gene therapy. Furthermore, UTMD-mediated Foxp3-miRNA/shRNA may relieve the immunosuppressive function of Tregs in patients with HCC in vitro, and partially inhibit the tumor growth in HCC mice through enhancing immunologic function and suppressing the production of VEGF. The present study is not without limitations; the long-term effects of UTMD-mediated Foxp3-miRNA/shRNA on immunologic function and tumor growth remain unclear. Therefore, the safety and efficacy of UTMD-mediated Foxp3-miRNA/shRNA should be further investigated in the future.
